New, late-breaking data show lebrikizumab responders reported long-lasting results at one year of treatment across measures of improvement in skin clearance, itch and disease extent and severityResults
London [UK]/ Mahwah (New Jersey) [US], Mumbai (Maharashtra) [India], August 31 (ANI/PRNewswire): Hikma Pharmaceuticals PLC (Hikma, Group), the multinational pharmaceutical company, and Glenmark Specialty S.A., a subsidiary of Glenmark Pharmaceuticals Ltd. (Glenmark) - an innovation driven global pharmaceutical company announced the launch of RYALTRIS (olopatadine hydrochloride and mometasone furoate nasal spray) in the US. RYALTRIS is approved by the US Food and Drug Administration (FDA) for the treatment of symptoms of seasonal allergic rhinitis (SAR) in adult and pediatric patients 12 years of age and older. This launch builds upon Hikma's leading position as one of the largest US providers of nasally administered medicines used for treating seasonal allergies and advances its objective of growing its specialty business in the US. RYALTRIS is the only fixed-dose combination therapy that provides relief for the symptoms of SAR, both nasal and ocular in one easy-to-use nasal spray.
MONDAY, Aug. 22, 2022 (HealthDay News) For patients receiving trastuzumab deruxtecan (T-DXd) monotherapy, the incidence of adjudicated drug-related interstitial lung disease (ILD)/pneumonitis is 15.4 percent, according to a study
At the primary analysis, the trial did not meet its primary endpoint of overall survival (OS) The safety profile was consistent with previously reported studies of Onivyde (irinotecan liposomal